期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤坏死因子相关凋亡诱导配体诱导HeLa细胞凋亡的差异蛋白质组分析 被引量：1

Differential proteomic analysis of HeLa cells induced by TRAIL
下载PDF
导出
摘要 目的比较分析肿瘤坏死因子相关凋亡诱导配体(TNF-related apoptosis-inducing ligand,TRAIL)诱导人宫颈癌细胞系HeLa细胞凋亡前后蛋白质组中的差异表达蛋白,以进一步了解TRAIL的作用机制。方法以TRAIL诱导人宫颈癌细胞系HeLa细胞凋亡为模型,用双向电泳技术分离HeLa全细胞蛋白质,MALDI-TOF质谱鉴定,MS-FIit数据库分析,RT-PCR半定量方法检测JNK2的表达。结果鉴定得到12个明显的差异蛋白点,其中8个蛋白点上调,4个蛋白点下调。JNK2的表达与TRAIL有良好的量效关系。结论JNKK、MAPKAPK-2、Dip13beta、SHPS-1、DDBb、JEM-1、Macoilin、Leucine-rich repeat-containing protein14、Ena/VASP-likeprotein、PTPase-MEG2、GRB10 adaptor protein、THUMP domain-containing pro-tein1为TRAIL诱导HeLa细胞凋亡的新的相关蛋白。 Objective To detect the differential proteins between HeLa cells treated and untreated by TRAIL so as to further understand the mechanisms of apoptosis induced by TRAIL in HeLa cells. Methods The differential proteins were observed by 2D electrophoresis, identified by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry （MALDI-TOF-MS） and analyzed by MS Fit. The expression of JNK2 was examined by semi-quantitative RT-PCR method. Results There were twelve differential proteins between HeLa cells treated and untreated by TRAIL, 8 up-regulated and 4 down-regulated. There was a good dose-effect relationship between JNK2 and TRAIL. Conclusion JNKK, MAPKAPK-2, Dipl3 beta, SHPS-1, DDBb, JEM-1, Macoilin, Leucine-rich repeat-containing protein 14, Ena/VASP-like protein, PTPase-MEG2, GRB10 adaptor protein, THUMP domain-containing protein 1 take part in the apoptosis of HeLa cells induced by TRAIL.
作者 赖国旗 邱宗荫 向廷秀 宋敏 胡小龙 何明忠 谭冬梅
机构地区 重庆医科大学 重庆医科大学 重庆医科大学 重庆医科大学药学院 重庆医科大学临床医学一系
出处 《第三军医大学学报》 CAS CSCD 北大核心 2008年第4期318-321,共4页 Journal of Third Military Medical University
基金 国家自然科学基金(30500234)~~
关键词 肿瘤坏死因子相关凋亡诱导配体 HELA细胞 蛋白质组分析 RT-PCR TNF-related apoptosis-inducing ligand HeLa cells Proteomics RT-PCR
分类号 R394-33 [医药卫生—医学遗传学] R73-362 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Kaliberov S A, Buchsbaum D J. Gene delivery and gene therapy of prostate cancer[J]. Expert Opin Drug Deliv, 2006, 3 ( 1 ) : 37 - 51.
  • 2王正兵,贾筱琴,陈兵,李厚达.TRAIL真核表达质粒的构建及抑制肝癌生长的实验研究[J].中国普外基础与临床杂志,2005,12(3):261-264. 被引量：6
  • 3Mikami T, Koyama T, Koyama T, et al. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines [J]. Anticancer Res, 2006, 26(2A) : 1153 - 1160.
  • 4Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway[J]. Cell Signal, 2006, 18( 11 ) : 1897 - 1905.
  • 5Pfannenschmid F, Wimmer V C, Rios R M, et al. Chlamydomonas D1P13 and human NA14: a new class of proteins associated with microtubule structures is involved in cell division [ J]. J Cell Sci, 2003, 116 (Pt 8) : 1449 - 1462.
  • 6Neznanov N, Neznanova L, Kondratov R V, et al. Dominant negative form of signal-regulatory protein-alpha ( SIRPalpha/SHPS-1 ) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B[J].J Biol Chem, 2003 , 278(6) : 3809 -3815.
  • 7Zolezzi F, Linn S. Studies of the murine DDB1 and DDB2 genes[J]. Gene, 2000 , 245(1): 151 -159.
  • 8Klostermann A, Lutz B, Gertler F, et al. The orthologous human and murine semaphorin 6A-1 proteins ( SEMA6A-1/Sema6A-1 ) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal zyxin-like domain [ J ]. J Biol Chem, 2000, 275 (50) : 39647 - 39653.
  • 9Okino K, Konishi H, Doi D, et al. Up-regulation of growth factor receptor-bound protein 10 in cervical squamous cell carcinoma[ J]. Oncol Rep, 2005, 13(6) : 1069 - 1074.
  • 10Langlais P, Dong L Q, Ramos F J, et al. Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10 [J]. Mol Endocrinol, 2004, 18(2) : 350 -358.

二级参考文献10

  • 1Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis [J]. Immunity, 1995; 3(6):673.
  • 2Gura T. How TRAIL kills cancer cells, but not normal cells [J]. Science, 1997; 277(5327):768.
  • 3Wu Z, O'Reilly MS, Folkman J, et al. Suppression of tumor growth with recombinant murine angiostatin [J]. Biochem Biophys Res Commun, 1997; 236(3):651.
  • 4Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4 [J]. Biochem Biophys Res Commun, 2000; 269(1):179.
  • 5Hu WH,Johnson H,Shu HB.Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kB and JNK activation and apoptosis through distinct pathways [J]. J Biol Chem, 1999; 274(43):30603.
  • 6Ashkenazi A, Dixit VM. Death receptor: signaling and modulation [J]. Science, 1998; 281(5381):1305.
  • 7Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer [J]. Neoplasia, 2001; 3(6):535.
  • 8Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL--on a path to cancer immunotherapy [J]. Immunity, 2003; 18(1):1.
  • 9石景森,周连锁,朱爱军,杨毅军.肿瘤坏死因子及其受体在胆囊癌及结石性胆囊炎中的表达[J].中国普外基础与临床杂志,2004,11(1):40-44. 被引量：6
  • 10陆云飞,覃新干,曾健,林进令,廖清华.肿瘤坏死因子α基因转导的人肝癌细胞疫苗对小鼠肝癌移植瘤的影响[J].中国普外基础与临床杂志,2003,10(4):366-369. 被引量：2

共引文献5

同被引文献13

  • 1Stoschitzky K, Egginger G, Zernig G, et al. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies [ J ]. Chirality, 1993,5 ( 1 ) : 15 - 19.
  • 2Oparil S, Zaman M A, Calhoun D A. Pathogenesis of hypertension [J]. Ann Intern Med, 2003, 139(9) : 761 -776.
  • 3Williams B, Lacy P S, Thom S M, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study [J]. Circulation, 2006, 113(9): 1213-1225.
  • 4National Institute for Health and Clinical Excellence (NICE). Clinical guideline 34 [ M ]. Hypertension : management of hypertension in a- dults in primary care. London: 2006: 8.
  • 5Aursnes I, Osnes J B, Tvete I F, et al. Does atenolol differ from other beta-adrenergic blockers? [ J]. BMC Clin Pharmacol, 2007, 7: 4.
  • 6Mohammed S, Kraiczek K, Pinkse M W, et al. Chip-Based Enrich- ment and NanoLC-MS/MS Analysis of Phosphopeptides from Whole Lysates [J]. J Proteome Res, 2008, 7(4) : 1565 -1571.
  • 7Natarajan M, Stewart J E, Golemis E A, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells [ J]. Oncogene, 2006, 25 (12) : 1721 - 1732.
  • 8Dell'Angelica E C. AP-3-dependent trafficking and disease: the first decade[ J]. Curr Opin Cell Biol, 2009, 21 (4): 552- 559.
  • 9Fu Y J, Xiong S, Lovell M A, et al. Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice [ J]. Cell Mol Neurobiol, 2009, 29 ( 5 ) : 649 - 664.
  • 10Yego E C, Mohr S. siah-1 Protein is necessary for high glucose-in- duced glyceraldehyde-3-phosphate dehydrogenase nuclear accumula- tion and cell death in Muller cells [J]. J Biol Chem, 2010, 285 (5) : 3181 -3190.

引证文献1

二级引证文献2

第三军医大学学报
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部